Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment
Background/Objectives: The visual acuity (VA) outcomes after the first and second years of anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular oedema (DMO) were evaluated, and the factors associated with treatment success were investigated. Methods: Using...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/1/99 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587743750782976 |
|---|---|
| author | Qing Wen Helene Karcher David M. Wright Samriddhi Buxy Sinha Usha Chakravarthy Catarina Santos Franklin Igwe Recivall Salongcay Katie Curran Tunde Peto |
| author_facet | Qing Wen Helene Karcher David M. Wright Samriddhi Buxy Sinha Usha Chakravarthy Catarina Santos Franklin Igwe Recivall Salongcay Katie Curran Tunde Peto |
| author_sort | Qing Wen |
| collection | DOAJ |
| description | Background/Objectives: The visual acuity (VA) outcomes after the first and second years of anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular oedema (DMO) were evaluated, and the factors associated with treatment success were investigated. Methods: Using Medisoft electronic medical records (UK), this retrospective cohort study analysed VA outcomes, changes, and determinants in DMO patients at year 1 and year 2 after initial anti-VEGF injection. Descriptive analysis examined baseline demographics and clinical characteristics, while regression models were used to assess associations between these factors and changes in VA. Results: 728 DMO patients (1035 eyes) treated with anti-VEGFs (ranibizumab, aflibercept, or bevacizumab) at the Northern Ireland Mater Macular Clinic from 2008 to 2021 were evaluated. The mean age was 64.5 (SD 12.8) years, and 59.6% were male. In the first year, the median annual injection number and interval were 6.0 (IQR 5.0–8.0) and 6.1 weeks (IQR 5.4–7.8), respectively, and in the second year, they were 3.0 (IQR 2.0–5.0) and 10.0 weeks (IQR 6.5–20.1). In the first two treatment years, 83.4% and 79.8% of eyes had improved/stable VA (ISVA) respectively. The injection number, interval, baseline VA, age, and proliferative diabetic retinopathy (PDR) significantly impacted VA outcomes. Conclusions: Our study confirms the effectiveness of anti-VEGF treatments in improving or maintaining vision for DMO patients, consistent with previous real-world clinical data. An elder age, a better baseline VA, low annual injection numbers (<5), and less frequent injection intervals (≥12 weeks) were negatively associated with ISVA success in the first two years. These findings have implications for managing patient expectations, allocating resources, and understanding DMO clinical management. |
| format | Article |
| id | doaj-art-d4034441b4164fc5ba173455497ff1f3 |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-d4034441b4164fc5ba173455497ff1f32025-01-24T13:45:57ZengMDPI AGPharmaceutics1999-49232025-01-011719910.3390/pharmaceutics17010099Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF TreatmentQing Wen0Helene Karcher1David M. Wright2Samriddhi Buxy Sinha3Usha Chakravarthy4Catarina Santos5Franklin Igwe6Recivall Salongcay7Katie Curran8Tunde Peto9Centre for Public Health, Institute of Clinical Sciences, School of Medicine, Queen’s University Belfast, Belfast BT7 1NN, UKNovartis, Pharma AG, 4056 Basel, SwitzerlandCentre for Public Health, Institute of Clinical Sciences, School of Medicine, Queen’s University Belfast, Belfast BT7 1NN, UKNovartis, Pharma AG, 4056 Basel, SwitzerlandCentre for Public Health, Institute of Clinical Sciences, School of Medicine, Queen’s University Belfast, Belfast BT7 1NN, UKNovartis, Pharma AG, 4056 Basel, SwitzerlandNovartis, Pharma AG, 4056 Basel, SwitzerlandCentre for Public Health, Institute of Clinical Sciences, School of Medicine, Queen’s University Belfast, Belfast BT7 1NN, UKCentre for Public Health, Institute of Clinical Sciences, School of Medicine, Queen’s University Belfast, Belfast BT7 1NN, UKCentre for Public Health, Institute of Clinical Sciences, School of Medicine, Queen’s University Belfast, Belfast BT7 1NN, UKBackground/Objectives: The visual acuity (VA) outcomes after the first and second years of anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular oedema (DMO) were evaluated, and the factors associated with treatment success were investigated. Methods: Using Medisoft electronic medical records (UK), this retrospective cohort study analysed VA outcomes, changes, and determinants in DMO patients at year 1 and year 2 after initial anti-VEGF injection. Descriptive analysis examined baseline demographics and clinical characteristics, while regression models were used to assess associations between these factors and changes in VA. Results: 728 DMO patients (1035 eyes) treated with anti-VEGFs (ranibizumab, aflibercept, or bevacizumab) at the Northern Ireland Mater Macular Clinic from 2008 to 2021 were evaluated. The mean age was 64.5 (SD 12.8) years, and 59.6% were male. In the first year, the median annual injection number and interval were 6.0 (IQR 5.0–8.0) and 6.1 weeks (IQR 5.4–7.8), respectively, and in the second year, they were 3.0 (IQR 2.0–5.0) and 10.0 weeks (IQR 6.5–20.1). In the first two treatment years, 83.4% and 79.8% of eyes had improved/stable VA (ISVA) respectively. The injection number, interval, baseline VA, age, and proliferative diabetic retinopathy (PDR) significantly impacted VA outcomes. Conclusions: Our study confirms the effectiveness of anti-VEGF treatments in improving or maintaining vision for DMO patients, consistent with previous real-world clinical data. An elder age, a better baseline VA, low annual injection numbers (<5), and less frequent injection intervals (≥12 weeks) were negatively associated with ISVA success in the first two years. These findings have implications for managing patient expectations, allocating resources, and understanding DMO clinical management.https://www.mdpi.com/1999-4923/17/1/99diabetic macular oedemaanti-VEGF treatmentvisual acuityinjection treatment |
| spellingShingle | Qing Wen Helene Karcher David M. Wright Samriddhi Buxy Sinha Usha Chakravarthy Catarina Santos Franklin Igwe Recivall Salongcay Katie Curran Tunde Peto Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment Pharmaceutics diabetic macular oedema anti-VEGF treatment visual acuity injection treatment |
| title | Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment |
| title_full | Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment |
| title_fullStr | Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment |
| title_full_unstemmed | Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment |
| title_short | Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment |
| title_sort | visual acuity outcomes and influencing factors in a cohort of uk real world diabetic macular oedema patients during the first two years of anti vegf treatment |
| topic | diabetic macular oedema anti-VEGF treatment visual acuity injection treatment |
| url | https://www.mdpi.com/1999-4923/17/1/99 |
| work_keys_str_mv | AT qingwen visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT helenekarcher visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT davidmwright visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT samriddhibuxysinha visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT ushachakravarthy visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT catarinasantos visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT franklinigwe visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT recivallsalongcay visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT katiecurran visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment AT tundepeto visualacuityoutcomesandinfluencingfactorsinacohortofukrealworlddiabeticmacularoedemapatientsduringthefirsttwoyearsofantivegftreatment |